PE ratio relative to earnings growth — is the valuation justified?
| Symbol | Company | PEG | P/E | Growth | vs OGN |
|---|---|---|---|---|---|
| AZN | AstraZeneca PLC | 0.59 | 23.6 | 40.2% | — |
| LLY | Eli Lilly and Company | 1.44 | 39.8 | 27.5% | — |
| NVS | Novartis AG | 1.49 | 22.9 | 15.4% | — |
| BMY | Bristol-Myers Squibb Company | 2.73 | 14.2 | 5.2% | — |
| MRK | Merck & Co., Inc. | 5.13 | 108.8 | 21.2% | — |